Will the Bankruptcy of “Forever 21” Strengthen IP Rights?
For the second time since its founding in 1984, the fast-fashion movement leader, Forever 21, has filed for bankruptcy and is expected to close its over 350 U.S. locations and...
Rare Disease Therapies Gain Momentum With Regulatory Support and Continued Market Growth
The landscape for rare disease treatments appears to be evolving rapidly, thanks to a confluence of regulatory momentum and a booming market forecast. Statements from key federal figures in recent...
Knobbe Martens, Dozens of Firm Partners Recognized in Legal 500 U.S.A. Guide
Firm again receives standout rankings in multiple practice areas, including prosecution, trademarks, licensing, and litigation IRVINE, Calif., June 17, 2025 – Knobbe Martens is proud to announce that the firm...
Knobbe Martens Celebrated as “Excellent IP Firm,” Dozens of Partners Recognized for Top-Tier Patent Work in IAM Patent 1000 Guide
IRVINE, Calif., June 3, 2025 – Knobbe Martens is pleased to share that the firm and two dozen of its partners from offices throughout the country have been featured in...
Suspension of the Climate Change Mitigation Pilot Program: What Happens Now?
Effective January 28, 2025, the new administration suspended the Climate Change Mitigation Pilot Program (CCMPP) at the United States Patent and Trademark Office (USPTO).[1] The USPTO had instituted this program...
Heading Towards an Optimistic Initial Public Offerings (IPOs) Resurgence in 2025?
On January 16th, 2025, GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led by Evidity Health Capital and joined...
End of an Era: The After Final Consideration Pilot Program 2.0 Concludes
The sun is officially setting on the United States Patent and Trademark Office’s (USPTO) After Final Consideration Pilot Program 2.0 (AFCP 2.0)[1]. This program, which has been instrumental in facilitating...
Settlements Don’t Close the Door: Antitrust Claims Follow IPR Challenges in Life Sciences
In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson[1], the plaintiffs successfully overcame a motion to dismiss. At the heart of the case is J&J’s legal...
FDA Approves Colony Stimulating Factor-1 Receptor (Csf-1R) Blocking Antibody for Treatment of Chronic Graft-Versus-Host Disease (Cgvhd)
On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO (axatilimab-csfr) developed by Incyte Corporation (and in-licensed from Syndax Pharmaceuticals), for treatment of chronic graft-versus-host disease (cGvHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Understanding the Dangers of Counterfeit Drugs Through the Lens of Fake Ozempic
The June 2024 issue of Vanity Fair included the provocative headline: “Why Counterfeit Ozempic Is a Global-Growth Industry." Novo Nordisk’s patented drug Ozempic® (semaglutide injection) was first approved by the FDA in 2017 for the treatment of type 2 diabetes. A few years later, clinical trials demonstrated that Ozempic® could also be used for weight loss in individuals without diabetes who had previously struggled to lose weight. News of the “miraculous weight loss” achieved with Ozempic® (and its sister drug Wegovy®) led to widespread demand for the drug and global shortages.
Knobbe Martens’ Across-the-Board Strength in Patent Work Recognized in IAM 2024 Patent 1000 Guide
IRVINE, Calif., June 21, 2024 – Knobbe Martens is proud to announce that multiple practices across the firm and two dozen partners were recognized nationally and regionally for outstanding work...
Dozens of Knobbe Martens Partners and Practices Receive Standout Rankings from Legal 500
The firm and its partners were recognized for strengths across all areas of IP, including patent prosecution, trademarks, and patent litigation—including ITC litigation IRVINE, Calif., June 17, 2024 – Knobbe...
FDA Panel Votes Against MDMA-Assisted Talk Therapy
On June 4, 2024, a panel of experts advising the Food and Drug Administration (FDA) on the use of the psychedelic midomafetamine (MDMA) for post-traumatic stress disorder (PTSD) voted 9-2 that MDMA in combination with talk therapy is not effective for treating PTSD, and 10-1 that the benefits of MDMA treatment do not outweigh its risks. The panel had reviewed Lykos Therapeutics ’s new drug application and associated clinical research related to treating PTSD using MDMA, also known by its street name ecstasy, in combination with talk therapy.
Medicare Drug Price Negotiation Program Steadily Progressing Despite Lawsuits
The Biden Administration’s Inflation Reduction Act (IRA)’s Medicare drug price negotiation program, which allows Medicare to directly negotiate prices with drugmakers, has faced several legal challenges.
Introduced Patent Eligibility Restoration Act of 2023 (PERA) Seeks to Revitalize Patent Eligibility Standards
On June 6, 2023, the Senate Judiciary Committee's Subcommittee on Intellectual Property introduced a Bill entitled “Patent Eligibility Restoration Act of 2023” (PERA) aiming to amend the law relating to patent subject matter eligibility. The bill seeks to eliminate the so-called “judicial exceptions” to patent eligibility that have led to a significant number of “inventions” being deemed ineligible for patent protection. Additionally, this legislation seeks to clarify the confusion and inconsistency brought about by the Alice/Mayo framework, which has been criticized for its failure to provide a clear and consistent standard for patent eligibility, negatively impacting the protection of innovations in various fields.
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
On October 27th, 2023, the U.S. Food and Drug Administration (FDA) approved LOQTORZITM (toripalimab-tpzi), developed by Coherus BioSciences, Inc., and Shanghai Junshi Biosciences Co., Ltd., for two indications: 1) in...
FDA Approves Generic Fluorescein Injection
On September 26, 2023, Nexus Pharmaceuticals, LLC announced that it had received approval from the U.S. Food and Drug Administration (FDA) for Fluorescein Injection, USP. Nexus Pharmaceuticals is a maker of generic drugs.
Reseller or Distributor Beware? Downstream Liability for Infringing a Patented Process
As retailers or distributors that are not manufacturers of a product, companies may believe they cannot infringe a patent claiming how the product is made. After all, the retailers or distributors are not performing any steps of the patented manufacturing process. The companies may have no say in, or even be aware of how the product is manufactured. The companies may conclude they are insulated from liability based simply on being downstream from the manufacturing process.
IAM 2023 Patent 1000 Guide Recognizes More Than Two Dozen Knobbe Martens Partners and Practices
IRVINE, CALIF., June 26, 2023 – Knobbe Martens is pleased to announce that 23 of the firm’s partners were recognized as leading patent professionals and ranked nationally or regionally in the...
Knobbe Martens and Attorneys Earn Top Distinctions as IP Leaders by Legal 500
IRVINE, CALIF., June 7, 2023 – Knobbe Martens is pleased to announce it has once again been recognized for having some of the leading intellectual property practices and practitioners in...
Recessions and Patent Applications: Navigating the Ups and Downs of the Innovation Economy
As predictions of an economic recession in the United States loom, 2023 has started with extensive layoffs throughout the tech industry. Though not to an equal degree, the biotechnology, pharmaceutical, and life science industries have not been excluded from employment cuts. In January, Verily, the healthcare and life sciences subsidiary of Alphabet, Inc., announced a restructuring that would cut about 15% of its workforce. [1] Likewise, several other biotech giants, including Thermo Fisher Scientific and Grifols, have disclosed plans to decrease workforce in the coming quarters. [2]
